Loading news...
Elo Mutual Pension Insurance Co lifted its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 39.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 89,674 shares of the medical research company's stock after acquiring an additional 25,562 shares during the
Edwards Lifesciences Corporation (EW) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Edwards Lifesciences Corporation (EW) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
IRVINE, Calif.--(BUSINESS WIRE)--At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart disease can live longer, healthier lives. As part of this commitment, Edwards announced the impact and renewed vision for Every Heartbeat Matters, its signature global health initiative, to help 2 million more patients facing barriers worldwide access.
ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.
Lansforsakringar Fondforvaltning AB publ boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE: EW) by 4.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 273,323 shares of the medical research company's stock after acquiring an
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026 at 10:00 a.m. ET at the Barclays 28th Annual Global Healthcare Conference Wednesday, March 11, 2026 at 10:00 a.m. ET at the Leerink Global Healthcare Conference A live webcast of each presentation will be available on the Edwards investor relations website at http://ir.edwards.com/, wit.
U.S. medical device maker Edwards Lifesciences has scrapped its anti-copycat policy that triggered a complaint from an Indian rival, EU antitrust regulators said on Monday as they closed their investigation into the company.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in Citi's Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial officer, is scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edwards Lifesciences Edwards L.
Edwards Lifesciences Corporation (NYSE: EW - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-seven analysts that are covering the company, MarketBeat Ratings reports. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
With Edwards Lifesciences getting a key earnings report out of the way, the uncertainties hanging over EW stock has cleared for the bulls.
Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.
Total Sales: $1.57 billion, grew 11.6% year over year.Adjusted EPS: $0.58, lower due to higher spending and tax rate.GAAP EPS: $0.11, impacted by one-time char
Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript
The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Edwards Lifesciences on Tuesday forecast 2026 profit above estimates, betting on robust demand for its artificial heart valves and other medical devices, sending its shares up 3% in after-hours trading.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook Q4 sales grew 13.3% to $1.57 billion1, constant currency2 sales grew 11.6% Q4 TAVR sales grew 12.0% to $1.16 billion1; constant currency2 sales grew 10.6% Q4 TMTT sales grew more than 40% to $156 million1 from repair and replacement therapies Q4 EPS of $0.111; adjusted2 EPS of $0.58 FY 2025 sales grew 11.5%, 10.7% constant cu.
Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market.